These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 28987520)

  • 61. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?
    Di Maio VC; Cento V; Aragri M; Paolucci S; Pollicino T; Coppola N; Bruzzone B; Ghisetti V; Zazzi M; Brunetto M; Bertoli A; Barbaliscia S; Galli S; Gennari W; Baldanti F; Raimondo G; Perno CF; Ceccherini-Silberstein F;
    J Hepatol; 2018 Mar; 68(3):597-600. PubMed ID: 28939133
    [No Abstract]   [Full Text] [Related]  

  • 62. "Empirical" retreatment of patients with chronic hepatitis C who failed a first direct-acting antiviral-based regimen.
    Kramer L; Laurain A; Sultanik P; Trémeaux P; Méritet JF; Rosenberg AR; Pol S
    J Hepatol; 2017 Dec; 67(6):1340-1342. PubMed ID: 28843657
    [No Abstract]   [Full Text] [Related]  

  • 63. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.
    Ahmed A; Felmlee DJ
    Viruses; 2015 Dec; 7(12):6716-29. PubMed ID: 26694454
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options.
    Loggi E; Vukotic R; Andreone P
    Expert Rev Anti Infect Ther; 2018 Nov; 16(11):833-838. PubMed ID: 30336699
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hepatitis C Virus and Antiviral Drug Resistance.
    Kim S; Han KH; Ahn SH
    Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants.
    Premoli C; Aghemo A
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):76-87. PubMed ID: 26448306
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C.
    Thiam A; Conway B
    Drugs Today (Barc); 2018 Apr; 54(4):237-244. PubMed ID: 29869645
    [TBL] [Abstract][Full Text] [Related]  

  • 69. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy.
    Chayama K; Hayes CN
    Viruses; 2015 Oct; 7(10):5328-42. PubMed ID: 26473914
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hepatitis C virus resistance to the new direct-acting antivirals.
    Esposito I; Trinks J; Soriano V
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Highly active anti-hepatitis C therapy: seven lessons from HIV.
    Thomas DL
    Antivir Ther; 2012; 17(6 Pt B):1183-8. PubMed ID: 23186629
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.
    Halfon P; Scholtès C; Izopet J; Larrat S; Trimoulet P; Zoulim F; Alric L; Métivier S; Leroy V; Ouzan D; de Lédinghen V; Mohamed S; Pénaranda G; Khiri H; Thélu MA; Plauzolles A; Chiche L; Bourlière M; Abravanel F
    J Hepatol; 2018 Mar; 68(3):595-597. PubMed ID: 28987520
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.